2.77
price down icon4.81%   -0.14
after-market Handel nachbörslich: 2.83 0.06 +2.17%
loading
Schlusskurs vom Vortag:
$2.91
Offen:
$2.81
24-Stunden-Volumen:
1.60M
Relative Volume:
1.63
Marktkapitalisierung:
$485.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-8.3939
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
-2.12%
1M Leistung:
+11.24%
6M Leistung:
-34.67%
1J Leistung:
-44.38%
1-Tages-Spanne:
Value
$2.68
$2.88
1-Wochen-Bereich:
Value
$2.61
$2.94
52-Wochen-Spanne:
Value
$2.31
$5.34

Savara Inc Stock (SVRA) Company Profile

Name
Firmenname
Savara Inc
Name
Telefon
51285113796
Name
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Name
Mitarbeiter
0
Name
Twitter
@SavaraPharma
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
SVRA's Discussions on Twitter

Vergleichen Sie SVRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SVRA
Savara Inc
2.77 485.68M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Savara Inc Stock (SVRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Eingeleitet Wells Fargo Overweight
2024-11-13 Herabstufung Evercore ISI Outperform → In-line
2024-02-15 Eingeleitet JMP Securities Mkt Outperform
2023-11-07 Eingeleitet Guggenheim Buy
2023-05-16 Hochstufung Jefferies Hold → Buy
2023-03-31 Herabstufung Jefferies Buy → Hold
2021-03-16 Eingeleitet Piper Sandler Overweight
2021-03-15 Eingeleitet Oppenheimer Outperform
2019-06-13 Bestätigt H.C. Wainwright Buy
2019-06-13 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 Herabstufung Ladenburg Thalmann Buy → Neutral
2018-08-13 Fortgesetzt ROTH Capital Neutral
2018-01-03 Eingeleitet Ladenburg Thalmann Buy
2017-09-27 Fortgesetzt ROTH Capital Buy
2017-09-22 Eingeleitet Jefferies Buy
2017-09-11 Eingeleitet JMP Securities Mkt Outperform
Alle ansehen

Savara Inc Aktie (SVRA) Neueste Nachrichten

pulisher
06:16 AM

Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - MarketScreener

06:16 AM
pulisher
05:05 AM

SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq

05:05 AM
pulisher
06:59 AM

Savara Inc ends sales agreement with Evercore - Investing.com

06:59 AM
pulisher
06:17 AM

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com

06:17 AM
pulisher
03:34 AM

Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

03:34 AM
pulisher
01:18 AM

What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World

01:18 AM
pulisher
Mar 30, 2025

HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Savara enters loan and security agreement with Hercules Capital - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Savara Inc. (SVRA) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Savara secures $200M loan to support respiratory drug launch - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph

Mar 26, 2025
pulisher
Mar 26, 2025

Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 26, 2025
pulisher
Mar 24, 2025

Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

Savara Inc. to Present at Leerink Global Healthcare Conference - MSN

Mar 18, 2025
pulisher
Mar 17, 2025

Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan

Mar 17, 2025
pulisher
Mar 13, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Mar 13, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register

Mar 08, 2025
pulisher
Mar 07, 2025

Savara, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire

Mar 06, 2025
pulisher
Mar 06, 2025

Game-Changing Finger-Prick Test Could Transform Rare Lung Disease DiagnosisWhat Makes It Special? - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

Savara Announces Participation in the Leerink Global Healthcare Conference - Joplin Globe

Mar 03, 2025
pulisher
Mar 03, 2025

Rare Disease Biotech Savara Sets Key Investor Presentation at Leerink Conference - Stock Titan

Mar 03, 2025
pulisher
Feb 27, 2025

Savara (SVRA) Expected to Announce Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Savara Insiders Lose Out As Stock Sinks To US$2.56 - Simply Wall St

Feb 26, 2025
pulisher
Feb 24, 2025

SVRA stock touches 52-week low at $2.58 amid market challenges - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

SVRA stock touches 52-week low at $2.58 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 23, 2025

Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86 - Defense World

Feb 23, 2025
pulisher
Feb 18, 2025

Savara Inc. Awards Stock Options and RSUs to New Employees - MSN

Feb 18, 2025

Finanzdaten der Savara Inc-Aktie (SVRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Kapitalisierung:     |  Volumen (24h):